Salvage focal brachytherapy in castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Rep. 2022 Apr 28;5(4):233-236. doi: 10.1002/iju5.12442. eCollection 2022 Jul.

Abstract

Introduction: Treatment strategy for castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.

Case presentation: We described a case of castration-resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate-specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate-specific antigen progression-free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months.

Conclusion: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration-resistant prostate cancer with neuroendocrine differentiation.

Keywords: castration‐resistant prostate cancer (CRPC) with neuroendocrine differentiation; prostate cancer; salvage focal brachytherapy.